Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International journal of pharmaceutics

• Publication date

  2012-09-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijpharm.2012.05.028PMID 22633931PMCID PMC3402233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

  2012influential reference
• The controversial role of ABC transporters in clinical oncology.

  2011cited by this paper
• Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

  2011influential reference
• The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

  2011cited by this paper
• Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux

  2010influential reference
• Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

  2010cited by this paper
• Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.

  2010cited by this paper
• Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

  2010influential reference
• Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.

  2010cited by this paper
• Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

  2009cited by this paper
• Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human.

  2009cited by this paper
• A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET

  2009cited by this paper
• The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs

  2009cited by this paper
• Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

  2009influential reference
• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

  2009cited by this paper
• An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

  2009influential reference
• Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

  2008cited by this paper
• Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model

  2008cited by this paper
• Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

  2008cited by this paper
• Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar

  2007cited by this paper
• The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).

  2006cited by this paper
• Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

  2006cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

  2005cited by this paper
• The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

  2005influential reference
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Role of efflux pumps and metabolising enzymes in drug delivery

  2005cited by this paper
• Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography

  2005cited by this paper
• mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

  2005cited by this paper
• Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.

  2005cited by this paper
• The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model

  2004cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with Rapamycin

  1998cited by this paper

• Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors

  2026cites this paper
• Targeting protein synthesis pathways in MYC-amplified medulloblastoma

  2025cites this paper
• Dual inhibitors of P-glycoprotein and breast cancer resistance protein for overcoming the blood–brain barrier: in silico discovery and preclinical evaluation

  2025cites this paper
• Everolimus in pituitary tumor: a review of preclinical and clinical evidence

  2024cites this paper
• Advances and perspectives on pharmacological activities and mechanisms of the monoterpene borneol.

  2024cites this paper
• protein kinase inhibitors as Targeted therapy for glioblastoma: A meta-analysis of randomized controlled clinical trials.

  2024cites this paper
• Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies

  2024cites this paper
• Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.

  2023cites this paper
• Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies

  2023cites this paper
• Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2.

  2023cites this paper
• RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.

  2023cites this paper
• The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

  2022cites this paper
• A multistage oral delivery system of PTX for improving oral bioavailability and enhancing anticancer efficacy

  2021cites this paper
• Frontiers in the treatment of glioblastoma: Past, present and emerging.

  2021cites this paper
• Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds

  2021cites this paper
• MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

  2021cites this paper
• Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

  2021cites this paper
• Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

  2021cites this paper
• Drug penetration in pediatric brain tumors: Challenges and opportunities

  2021cites this paper
• Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer

  2021cites this paper
• Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein

  2020cites this paper
• Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.

  2020cites this paper
• Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma

  2020cites this paper
• Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.

  2020cites this paper
• A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment

  2019cites this paper
• Brain distribution of a panel of EGFR inhibitors using cassette-dosing in wild-type and Abcb1/Abcg2 deficient mice

  2019cites this paper
• CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. Cancer Management and Research, 10, 3483-

  2019cites this paper
• (2018). Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. Cancer and

  2019cites this paper
• Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice

  2019cites this paper
• Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.

  2018cites this paper
• Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

  2018cites this paper
• Translational gap in ongoing clinical trials for glioma.

  2018cites this paper
• Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update

  2018cites this paper
• Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology

  2018cites this paper
• Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

  2018cites this paper
• Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma

  2018cites this paper
• Diffuse intrinsic pontine glioma: a multi-facetted and global view

  2017cites this paper
• Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.

  2017cites this paper
• Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

  2017cites this paper
• Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.

  2017cites this paper
• Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms

  2017cites this paper
• Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates

  2017cites this paper
• Transporter effects on cell permeability in drug delivery

  2017cites this paper
• Pharmacokinetic drug‐drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy

  2017cites this paper
• Chapter 14 – Vandetanib

  2017cites this paper
• Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma

  2016cites this paper
• Gyógyszertranszporterek szerepe a központi idegrendszerben

  2016cites this paper
• Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

  2016cites this paper
• A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection.

  2016cites this paper
• Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients

  2016cites this paper
• Pharmaceutical Targeting of the Brain.

  2016cites this paper
• [Role of drug transporters in the central nervous system].

  2016cites this paper
• Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.

  2016cites this paper
• Membrane Transporters in Physiological Barriers of Pharmacological Importance.

  2016cites this paper
• Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

  2016cites this paper
• Chinese guidelines on the management of renal cell carcinoma (2015 edition).

  2016cites this paper
• Toward precision medicine in glioblastoma: the promise and the challenges.

  2015cites this paper
• Novel Approaches for the Delivery of Biologics to the Central Nervous System

  2015cites this paper
• The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors

  2015cites this paper
• PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

  2015cites this paper
• ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors

  2015cites this paper
• Chinese guidelines on the management of renal cell carcinoma (2015 edition).

  2015cites this paper
• Prodrug approach to improve absorption of prednisolone.

  2015cites this paper
• Apical ABC transporters and cancer chemotherapeutic drug disposition.

  2015cites this paper
• TRAIL pathway is associated with inhibition of colon cancer by protopanaxadiol.

  2015cites this paper
• Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.

  2015cites this paper
• Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

  2015cites this paper
• A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

  2015influential citation
• Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier

  2015cites this paper
• Resistance to Targeted ABC Transporters in Cancer

  2015cites this paper
• Drug interactions with solid tumour-targeted therapies.

  2014cites this paper
• Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells

  2014cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2014cites this paper
• Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors

  2014cites this paper
• Challenges in the design of clinically useful brain-targeted drug nanocarriers.

  2014cites this paper
• Cancer Therapy : Preclinical P-Glycoprotein , CYP 3 A , and Plasma Carboxylesterase Determine Brain and Blood Disposition of themTOR Inhibitor Everolimus ( A fi nitor ) in Mice

  2014influential citation
• Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors

  2014cites this paper
• ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors

  2014cites this paper
• Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

  2014cites this paper
• Influence of active efflux transport on the distribution of targeted agents to brain tumors

  2014cites this paper
• Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.

  2014cites this paper
• Development and evaluation of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-nanoemulsification (SNE) technique

  2014cites this paper
• Role of Membrane Transporters in Drug Delivery, Drug Disposition And Drug-Drug Interactions

  2014influential citation
• P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice

  2014influential citation
• Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors

  2014cites this paper
• Review Special Focu S: combating Re S i S tance: oncology

  2013cites this paper
• CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.

  2013cites this paper
• ABCG2: recent discovery of potent and highly selective inhibitors.

  2013cites this paper
• Pharmacokinetic Assessment of Efflux Transport in Sunitinib Distribution to the Brain

  2013influential citation
• Development and evaluation of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-nanoemulsification (SNE) technique

  2013cites this paper
• Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

  2013cites this paper
• IMPROVING DELIVERY OF ELACRIDAR TO ENHANCE EFFICACY OF MOLECULARLY-TARGETED AGENTS IN TREATMENT OF GLIOBLASTOMA

  2012cites this paper